Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Average: 2021-2025

Historic Equity Average for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $12.5 million.

  • InMed Pharmaceuticals' Equity Average rose 42.18% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 42.18%. This contributed to the annual value of $11.3 million for FY2025, which is 6.31% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Equity Average stood at $12.5 million, which was up 22.34% from $10.2 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Equity Average registered a high of $14.7 million during Q4 2021, and its lowest value of $1.3 million during Q3 2023.
  • Moreover, its 3-year median value for Equity Average was $10.2 million (2024), whereas its average is $8.7 million.
  • Per our database at Business Quant, InMed Pharmaceuticals' Equity Average tumbled by 87.50% in 2023 and then soared by 600.80% in 2024.
  • InMed Pharmaceuticals' Equity Average (Quarterly) stood at $14.7 million in 2021, then decreased by 13.77% to $12.7 million in 2022, then plummeted by 87.40% to $1.6 million in 2023, then skyrocketed by 356.39% to $7.3 million in 2024, then skyrocketed by 42.18% to $12.5 million in 2025.
  • Its Equity Average was $12.5 million in Q3 2025, compared to $10.2 million in Q2 2025 and $6.6 million in Q1 2025.